REG - Diaceutics PLC - Full Year 2025 Trading Update

DiaceuticsAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260115:nRSO9630Oa&default-theme=true

RNS Number : 9630O  Diaceutics PLC  15 January 2026

Diaceutics Full Year 2025 Trading Update

 

Reported revenues expected to be £38.5 million, representing 20% growth and a
return to profitability

 

Revenue on a constant currency basis expected to show 24% growth in line with
analyst consensus estimates*

 

FY 2025 Adjusted EBITDA** expected to exceed analyst consensus estimates

 

Record order book of at least £36.8 million

 

ARR of at least £20.3 million

 

12% growth in number of customer therapeutic brands to 95

 

Second PMx commercialisation partnership signed in Q4 with an innovative US
Biotech underpinning another year of strong commercial growth

 

Additional top 10 global pharma customer confirmed as an enterprise-wide
engagement customer; continue to consistently work with 18 of top 20 global
pharma companies

 

The Company expects to deliver 25% revenue growth in FY 2026

 

New York, Belfast and London, 15 January 2026 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, today provides a trading update
for the year ended 31 December 2025 ('FY 2025'), highlighting strong revenue
growth, improved profitability and a record order book.

Ryan Keeling, Diaceutics' Chief Executive Officer, commented: "2025 marked a
step-change year for Diaceutics as we executed an ambitious value-creation
programme focused on scale, profitability and recurring revenues. Through
disciplined go-to-market execution and the comprehensive deployment of AI
across the business, we have accelerated our transition to a high-quality ARR
model with improving margins. We delivered another year of robust commercial
performance, underpinned by expanding adoption across therapeutic brands and
deeper enterprise-wide customer engagements. Importantly, this growth was
achieved against a more challenging industry backdrop, demonstrating both the
mission-critical nature of our offering and the resilience of our revenue
model. Our continued investment in agentic AI is now driving tangible
operating leverage, enhancing customer outcomes while improving internal
efficiency and scalability. As a result, we enter 2026 with a record order
book and a strong forward sales pipeline, providing clear visibility on future
growth. With strong commercial momentum, a scalable platform and a proven
execution engine, we are confident in delivering another year of high-quality
growth and continued value creation in 2026."

Trading Update to 31 December 2025

Reported revenues are expected to be £38.5 million (FY 2024: £32.2
million), representing growth of 20% in the year and equating to a 3-year
Compound Annual Growth Rate ('CAGR') of 25%. On a constant currency basis,
underlying revenue would equate to £40.0 million delivering a growth rate of
24%, which is in line with analyst consensus estimates*.

 

The Company returned to profitability (Profit After Tax) in FY 2025, and
Adjusted EBITDA** is expected to be above analyst consensus estimates*
representing growth of approximately 75% year-on-year ('YoY') and an Adjusted
EBITDA** margin of approximately 19%.

 

The visibility and sustainability of revenues continued to improve during the
year. Annual Recurring Revenue ('ARR') increased 21% and is expected to be in
excess of £20.3 million ($27.4 million) as at 31 December 2025 (£16.8
million ($21.1 million) at 31 December 2024), representing USD YoY ARR growth
in excess of 30%.  The multi-year nature of the order book continued to
expand and is expected to be in excess of £36.8 million as at 31 December
2025 (£24.9 million at 31 December 2024), a YoY growth of 48%.

 

Diaceutics added three new enterprise-wide customers in FY 2025, including its
second multi-year PMx commercialisation partnership with a leading US biotech.
PMx integrates real-time multi-modal data, lab networks, digital outreach and
peer-to-peer education to drive precision therapy adoption. Ten
enterprise-wide engagements are now live across 36 brands, generating £13.0
million in ARR (£10.6 million in FY 2024). Enterprise-wide engagements are
defined as customers deploying the DXRX platform across three or more of the
brands in their portfolio, or where Diaceutics is the primary
commercialisation partner for their precision medicine.

 

Diaceutics continues to work with 18 of the top 20 global pharma companies,
and supported a total of 53 customers across 95 therapeutic brands in FY 2025
(FY 2024: 52 customers and 85 therapeutic brands).

 

Outlook

·    lobal pharma and biotech customers are continuing to accelerate their
shift to precision medicine to improve patient access, capture lost revenue
and optimise commercial outcomes

·    Ongoing enhancements to the DXRX platform are delivering operational
leverage

·   Started to secure opportunities beyond precision medicine, supporting
new therapeutic brands and expanded revenue opportunities

·    The Company expects to deliver 25% revenue growth in FY 2026

 

All numbers stated are approximate and subject to audit.

* Analyst consensus estimates for FY 2025 revenue is £39.5 million and
Adjusted EBITDA is £7.1 million.

** Adjusted EBITDA is earnings before interest, tax, depreciation,
amortisation and exceptional items.

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer             Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer             investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)        Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network®.

 

Prior to publication the information communicated in this announcement was
deemed by the Company to constitute inside information for the purposes of
article 7 of the Market Abuse Regulations (EU) No 596/2014 as amended by
regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations No
2019/310 ('MAR'). With the publication of this announcement, this information
is now considered to be in the public domain.  The person responsible for
making this announcement on behalf of the Company is Nick Roberts, Chief
Financial Officer.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFFFFFLRISLIR



            Copyright 2019 Regulatory News Service, all rights reserved